217 related articles for article (PubMed ID: 36259523)
1. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
Andrillon A; Chevret S; Lee SM; Biard L
Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
[TBL] [Abstract][Full Text] [Related]
2. Dose-finding design and benchmark for a right censored endpoint.
Andrillon A; Chevret S; Lee SM; Biard L
J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
[TBL] [Abstract][Full Text] [Related]
3. Seamless phase I/II design for novel anticancer agents with competing disease progression.
Biard L; Lee SM; Cheng B
Stat Med; 2021 Sep; 40(21):4568-4581. PubMed ID: 34213022
[TBL] [Abstract][Full Text] [Related]
4. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
5. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
6. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
7. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
8. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
Zhou H; Chen C; Sun L; Zeng Z
Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
[TBL] [Abstract][Full Text] [Related]
9. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
10. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
11. SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.
Zhang Y; Guo B; Cao S; Zhang C; Zang Y
Pharm Stat; 2022 Sep; 21(5):960-973. PubMed ID: 35332674
[TBL] [Abstract][Full Text] [Related]
12. A simulation study of approaches for handling disease progression in dose-finding clinical trials.
Biard L; Cheng B; Manji GA; Lee SM
J Biopharm Stat; 2021 Mar; 31(2):156-167. PubMed ID: 32931360
[TBL] [Abstract][Full Text] [Related]
13. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
14. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
15. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
16. Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.
Yin G; Yang Z
Contemp Clin Trials Commun; 2020 Sep; 19():100650. PubMed ID: 32875142
[TBL] [Abstract][Full Text] [Related]
17. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
Mu R; Hu Z; Xu G; Pan H
BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
[TBL] [Abstract][Full Text] [Related]
18. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
[TBL] [Abstract][Full Text] [Related]
19. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
20. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
